Thermo Fisher Launched Gibco CHO-K1 Catalog Panel
The new product portfolio aims to streamline cell line development and protein production for biotech companies.
Updated on Oct. 7, 2026 in Biotech
Thermo Fisher Scientific has launched its new Gibco CHO-K1 Catalog Panel, a series of chemically defined media and feeds designed for protein production. The product line is specifically engineered to help development teams optimize their cell line processes.
Why it matters
The panel provides a suite of ready-to-use options that assist upstream process developers in identifying high-performing combinations for biologics. These cGMP-ready products are intended to support developers in navigating complex regulatory requirements.
The Gibco CHO-K1 Catalog Panel utilizes chemically defined, animal-origin-free formulations available in liquid or dry powder. Results from a 14-day fed-batch study on a CHO-K1 GS cell line showed up to 73% higher titer and 202% higher viable cell density.
The players
Thermo Fisher Scientific
This American supplier provides scientific instrumentation, reagents, and software for the global healthcare and research sectors.
The details
The panel offers multiple basal media and feed combinations, allowing teams to test various configurations to increase manufacturing efficiency. The components are available as off-the-shelf catalog items to accelerate development timelines.
Timeline
14-day: Duration of the fed-batch study performed on the CHO-K1 GS cell line.
The Big Picture
This release reflects the industry shift toward standardized, cGMP-ready components for CHO-K1 cell line protein production protocols. By automating the selection of high-performing media, the panel reduces the need for custom internal development.
Biotech developers can now access pre-validated, cGMP-ready media combinations to potentially shorten their time-to-market. These standardized components may reduce the trial-and-error burden for labs working with CHO-K1 cell lines.
The takeaway
Optimizing media and feed combinations remains a critical bottleneck for biologics manufacturing firms seeking higher yields. Leveraging catalog-based, validated panels can improve process reliability while maintaining compliance with international standards.
Further reading
Explore more about industry-standard Biotech advancements and process developments.
Source note: This article includes information reported by Selectscience.
